Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Bio-Techne, TECH
Summary: Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
- Last Price: $382.97
- Price Change: -$7.93, -2.03%
- Yearly Gain: -20.09%
- Market Cap: $15.34B
- P/E Ratio: 58.983
Here are 3rd party ratings for TECH:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Top 31% (78 out of 252)
What is the sentiment on the street regarding Bio-Techne ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Neutral
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in TECH or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on TECH before you decide to make any investment.
Click here for chart >>
Repligen, RGEN
Summary: Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.
- Last Price: $246.27
- Price Change: $2.97, 1.22%
- Yearly Gain: -4.46%
- Market Cap: $13.49B
- P/E Ratio: 87.967
Here are 3rd party ratings for RGEN:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 31% (78 out of 252)
What is the sentiment on the street regarding Repligen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Neutral
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in RGEN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RGEN before you decide to make any investment.
Click here for chart >>
Aldeyra Therapeutics, ALDX
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
- Last Price: $6.92
- Price Change: $0.68, 10.9%
- Yearly Gain: -34.80%
- Market Cap: $363.80M
- P/E Ratio: -5.638
Here are 3rd party ratings for ALDX:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 33% (84 out of 252)
What is the sentiment on the street regarding Aldeyra Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in ALDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ALDX before you decide to make any investment.
Click here for chart >>
CymaBay Therapeutics, CBAY
Summary: CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
- Last Price: $4.25
- Price Change: $0.13, 3.16%
- Yearly Gain: 4.83%
- Market Cap: $348.87M
- P/E Ratio: -3.108
Here are 3rd party ratings for CBAY:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 35% (87 out of 252)
What is the sentiment on the street regarding CymaBay Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in CBAY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CBAY before you decide to make any investment.
Click here for chart >>
Thanks for reading!